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ABSTRACT
Microtubule-binding drugs such as taxol are frontline treatments for a variety 
of cancers but exactly how they yield patient benefit is unclear. In cell culture, 
inhibiting microtubule dynamics prevents spindle assembly, leading to mitotic 
arrest followed by either apoptosis in mitosis or slippage, whereby a cell returns 
to interphase without dividing. Myeloid cell leukaemia-1 (Mcl-1), a pro-survival 
member of the Bcl-2 family central to the intrinsic apoptosis pathway, is degraded 
during a prolonged mitotic arrest and may therefore act as a mitotic death timer. 
Consistently, we show that blocking proteasome-mediated degradation inhibits 
taxol-induced mitotic apoptosis in a Mcl-1-dependent manner. However, this 
degradation does not require the activity of either APC/C-Cdc20, FBW7 or MULE, 
three separate E3 ubiquitin ligases implicated in targeting Mcl-1 for degradation. 
This therefore challenges the notion that Mcl-1 undergoes regulated degradation 
during mitosis. We also show that Mcl-1 is continuously synthesized during 
mitosis and that blocking protein synthesis accelerates taxol induced death-in-
mitosis. Modulating Mcl-1 levels also influences slippage; overexpressing Mcl-1 
extends the time from mitotic entry to mitotic exit in the presence of taxol, while 
inhibiting Mcl-1 accelerates it. We suggest that Mcl-1 competes with Cyclin B1 for 
binding to components of the proteolysis machinery, thereby slowing down the 
slow degradation of Cyclin B1 responsible for slippage. Thus, modulating Mcl-1 
dynamics influences both death-in-mitosis and slippage. However, because mitotic 
degradation of Mcl-1 appears not to be under the control of an E3 ligase, we suggest 
that the notion of network crosstalk is used with caution.
INTRODUCTION
Microtubule binding agents are used extensively 
to treat ovarian, breast, prostate and lung cancer, as 
well as various leukemias [1]. While these drugs have 
impressive clinical efficacy, exactly how they yield patient 
benefit is unclear [2, 3]. This is in part because inhibiting 
microtubule dynamics impacts multiple aspects of tumor 
biology [4, 5]. Interfering with microtubules becomes 
particularly acute during mitosis when the interphase 
microtubule array is disassembled in order to construct the 
spindle apparatus responsible for chromosome segregation 
and cell division [1]. Disrupting spindle assembly results 
in persistent activation of the spindle assembly checkpoint 
(SAC) leading to a prolonged mitotic arrest [6-8]. After a 
protracted mitosis, cells either undergo death in mitosis 
(DiM), or exit without completing cell division and 
return to interphase, a process known as slippage [9-11]. 
Following slippage, post-mitotic responses then induce 
cell cycle arrest, senescence or apoptosis [12]. In response 
to agents that perturb mitosis, failure to undergo DiM 
and/or failure to efficiently engage post-mitotic responses 
can lead to proliferation of cells with highly abnormal 
genomes [13, 14].
Whether a cell dies in mitosis or undergoes slippage 
is best explained by the competing-networks model [10]. 
This model posits that mitotic fate is dictated by two 
independent networks, one slowly generating a death 
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signal, the other slowly degrading Cyclin B1, leading 
to slippage. During a protracted arrest, Cyclin B1 levels 
slowly fall due to incomplete penetrance of the SAC [9]. 
Meanwhile, a poorly defined cell death signal becomes 
stronger [15]. Both networks contain thresholds and the 
fate of the cell is dictated by which threshold is breached 
first. Our understanding of the mechanisms responsible for 
Cyclin B1 degradation are well advanced [16]. However, 
much less is known about how apoptosis is regulated 
during a mitotic arrest.
Death in mitosis involves the intrinsic apoptosis 
pathway, with multiple members of the Bcl-2 family 
subject to regulation by mitosis-specific controls [17]. 
For example, the BH3-only pro-apoptotic protein Bim 
is ubiquitinated by the anaphase promoting complex 
(APC/C), an E3 ubiquitin ligase that also targets Cyclin B1 
for degradation [18]. Bid, another BH3-only pro-apoptotic 
protein, is phosphorylated by Cdk1 [19]. Pro-survival Bcl-
xL is also phosphorylated by Cdk1, weakening its ability 
to bind and inhibit pro-apoptotic proteins Bax and Bak [20, 
21]. Mcl-1 is phosphorylated and ubiquitinated in mitosis, 
and several protein kinases and E3 ubiquitin ligases have 
been implicated. Cdk1 phosphorylates Mcl-1 on serine 64 
and threonine 92, and when expressed in U2OS cells, Mcl-
1 T92A resists degradation and suppresses nocodazole-
induced apoptosis [22, 23]. Mcl-1 binds the APC/C co-
factor Cdc20 and has a putative D-box, an RXXL motif 
required for co-factor binding. Mutating the RXXL 
motif or inhibiting APC/C-Cdc20, either by depletion 
of Cdc20 or the APC subunit APC3, stabilizes Mcl-1 in 
mitotic-arrested U2OS cells [22]. These observations 
suggest a simple model whereby Mcl-1 is targeted for 
degradation during a mitotic arrest by Cdk1-dependent 
APC/C-Cdc20 ubiquitination. However, other mechanisms 
are also implicated. In interphase, Mcl-1 is targeted for 
degradation by FBW7, an F-box adapter involved in 
SCF-mediated ubiquitination [24, 25]. Inhibiting FBW7 
also stabilizes Mcl-1 in mitosis and enhances slippage 
[26]. The E3 ligase first shown to be involved in Mcl-
1 ubiquitination was MULE/HUWE1 [27]. Inhibiting 
MULE also stabilizes Mcl-1 in mitotic-arrested cells [28, 
29]. Reconciling these different observations is difficult 
but may reflect redundancy, cell line variation and/or ‘belt 
and braces’ protection to ensure that an overly protracted 
mitosis sensitizes cells to undergo apoptosis [17].
Despite these complexities, because Mcl-1 is 
degraded during a mitotic arrest, it could act as the death 
timer evoked by the competing-networks model [10, 30, 
31]. In its original formulation, the competing-networks 
model suggested that the two networks are independent 
[10]. Observations indicating that Mcl-1 interacts with 
both apoptotic and mitotic regulators, raises the possibility 
that there may however be crosstalk between the networks 
that define mitotic cell fate. To test this possibility, we 
analyzed the effect of Mcl-1 degradation on both death in 
mitosis and slippage.
RESULTS
Mcl-1 is synthesized and degraded in mitosis
RNAi-mediated inhibition of Mcl-1 can accelerate 
death in mitosis (DiM), at least in some cell lines [29, 
32]. In addition, Mcl-1 is degraded during a mitotic arrest 
[22]. This suggests that Mcl-1 degradation acts as a death 
in mitosis timer. If this is the case, then blocking Mcl-1 
degradation should delay DiM. To test this, we turned to 
RKO cells, a colon cancer line that typically undergoes 
DiM and rarely slips [10]. Consistent with previous 
reports, Mcl-1 levels fell when RKO cells were arrested in 
mitosis with taxol (Fig. S1A). Moreover, upon exposing 
taxol-arrested RKO cells to the proteasome inhibitor 
MG132, Mcl-1 levels increased (Fig. S1B). This indicates 
that not only is Mcl-1 degraded in mitosis, but that it 
is also synthesized during the arrest. Indeed, blocking 
protein synthesis with cycloheximide led to a rapid decline 
in Mcl-1 levels (Fig. S1C).
Next, we set out to determine whether blocking 
Mcl-1 degradation with MG132 delayed death in 
mitosis. However, because MG132 also blocks the slow 
degradation of Cyclin B1 it abolishes slippage which 
complicates interpretation of the results [9]. Therefore to 
focus on Mcl-1’s role in DiM, we created experimental 
conditions whereby slippage was prevented by expression 
of a stabilized version Cyclin B1, namely the R42A 
mutant [33]. Combining taxol with tet-induction of 
Cyclin B1 R42A completely blocked slippage: every cell 
we analyzed by time-lapse imaging underwent death in 
mitosis (Fig. 1A, Fig. S1D)
Addition of MG132 to taxol-treated Cyclin B1 
R42A cells had a profound effect. Whereas control cells 
died after an average of 10.2 hours, MG132-treated cells 
took on average 31.2 hours to commit to DiM (Fig. 1B, 
left panel, Fig. S1E, S1F). To determine whether Mcl-1 
was required for this prolonged survival, we used RNAi to 
inhibit Mcl-1. As an additional control we also performed 
Bcl-xL RNAi. Depletion of Mcl-1 and Bcl-xL levels 
accelerated DiM with cells taking on average 3.5 and 6.4 
hours, respectively. Strikingly, Mcl-1 RNAi completely 
reversed the effect of MG132. By contrast, Bcl-xL RNAi 
had little effect. Thus, the simplest explanation for these 
observations is that the prolonged death delay induced by 
MG132 is due to inhibition of Mcl-1 degradation.
Consistent with continued synthesis of Mcl-1 
maintaining survival during a mitotic arrest, addition of 
cycloheximide accelerated DiM (Fig. 1B, right panel). 
Interestingly, 26% of the cycloheximide-treated cells 
avoided DiM by undergoing slippage. Note that in the 
absence of taxol, the mitotic arrest induced by Cyclin 
B1 R42A is not fully penetrant (Fig. 1B, Fig. S1G); we 
therefore suspect that enhanced slippage in this case is 
caused by cycloheximide reducing mitotic synthesis of 
Cyclin B1, thereby accelerating Cyclin B1’s decline even 
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Figure 1: Mcl-1 is synthesized and degraded in mitosis. A. Cell fate profiles of RKO Cyclin B1 R42A cells following treatment 
with 0.1 μM taxol and 1 μg/ml tetracycline for 72 hours. B. Cell fate profiles of RKO Cyclin B1 R42A cells following a 24-hour transfection 
with Mcl-1 and Bcl-xL siRNAs before treatment with taxol, tetracycline (1 μg/ml) and MG132 (20 μM) or cycloheximide (CHX) (30 μg/
ml) at 10 hours. The dotted line shows when MG132 and cycloheximide were added. Only cells that had entered mitosis 2.5 hours before 
drug addition were analyzed.
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though DiM is also accelerated [34]. Taken together, these 
observations support the notion that Mcl-1 is a key mitosis 
survival factor and that degradation of Mcl-1 defines time 
to death during a protracted mitotic arrest.
Analysis of E3 ligases implicated in mitotic 
degradation of Mcl-1
Multiple E3 ligases are implicated in targeting 
Mcl-1 for degradation, including the APC/C-Cdc20 
[35]. Because the APC/C-Cdc20 is responsible for slow 
degradation of Cyclin B1 during a prolonged mitotic 
arrest, it is a good candidate for mitotic degradation of 
Mcl-1. If this is the case, then blocking APC/C-Cdc20 
should delay time to DiM in taxol-treated Cyclin B1 R42A 
cells. To test this we treated cells with two APC/C-Cdc20 
inhibitors, namely pro-TAME and Apcin (Fig. S2) [36, 
37]. In the absence of taxol and Cyclin B1 R42A, pro-
TAME blocked mitotic progression (Fig. 2A), consistent 
with APC/C-Cdc20 inhibition. In isolation, Apcin had 
little effect but enforced the pro-TAME-mediated block, 
resulting in 78% of the population undergoing DiM. 
Importantly, this effect was not due to SAC activation as 
a consequence of cohesion fatigue [38] because the Mps1 
inhibitor AZ3146 did not override the pro-TAME/Apcin-
induced arrest (Fig. 2B).
Having established that combining pro-TAME 
and Apcin efficiently blocks APC/C-Cdc20 activity in 
RKO cells, we asked whether this would delay time to 
death in taxol-treated Cyclin B1 R42A cells. However, 
when we analyzed the cumulative death frequency, there 
was no difference between cells treated with or without 
the pro-TAME/Apcin combination (Fig. 2C). As DiM 
kinetics in this cell line are responsive to modulation of 
Mcl-1 levels, this suggests that while the APC/C-Cdc20 
may contribute to Mcl-1 degradation during mitosis, it 
is not essential. Consistently, in contrast to MG132, the 
pro-TAME/Apcin combination did not stabilize Mcl-
1 levels in mitosis (Fig. 2D). We therefore turned to 
another E3 ligase implicated in Mcl-1 degradation, the 
SCF complex. Inhibition of the SCF subunit FBW7 by 
RNAi, either alone or in combination with proTAME/
Apcin, had no significant effect on Mcl-1 levels or the 
time to death in taxol-treated Cyclin B1 R42A cells 
(Fig. 2E, 2F). Moreover, RNAi-mediated inhibition 
of MULE, either alone or in combination with FBW7 
RNAi and/or proTAME/Apcin, had no significant effect 
on DiM (Fig. S3). Thus, in the context of this model 
system, we do not have any compelling evidence linking 
mitotic Mcl-1 degradation to APC/C-Cdc20, FBW7 and 
MULE. This could suggest that the modalities used here 
are simply not penetrant enough to have a significant 
inhibitory effect on Mcl-1 degradation. Alternatively, 
it could be that other mechanisms contribute to Mcl-
1 degradation even when APC/C-Cdc20, FBW7 and 
MULE are inhibited.
Analysis of Mcl-1’s putative D-box
Because inhibiting APC/C-Cdc20 and FBW7 had 
little effect on either Mcl-1 degradation or time to death, 
we turned to a more direct approach, namely mutating 
potential degrons in Mcl-1. In particular, we focused 
on a potential D-box. Note that D-boxes contain RXXL 
motifs and are typically found in APC/C-Cdc20 substrates 
[16]. Importantly, mutating an RXXL motif in Mcl-1 was 
previously shown to suppress its degradation in mitosis 
[22]. We therefore generated tet-inducible RKO cells 
expressing GFP-tagged wild type Mcl-1 and a mutant, 
Mcl-1RALA, where arginine 207 and leucine 210 in the 
RXXL motif are mutated to alanine (Fig. 3A). Consistent 
with Mcl-1’s pro-survival effect, tet-induction of the wild 
type protein delayed time to death in taxol from 13.1 hours 
to 18.4 hours (Fig. 3B). If the Mcl-1RALA mutant resisted 
mitotic degradation, then we expected that it might have 
a more penetrant effect on DiM. However, while Mcl-
1RALA also extended time to death in taxol, the effect was 
comparable to the wild type (Fig. 3B).
Immunoblotting suggested that the ectopic Mcl-
1 proteins were expressed at similar levels to the 
endogenous (Fig. 3A). We therefore asked whether forced 
overexpression might reveal a difference between the wild 
type and the Mcl-1RALA mutant. Moreover, we wanted to 
test the Mcl-1RALA mutant in cells expressing Cyclin B1 
R42A. Therefore, we used transient transfections of RKO 
cells to force overexpression. Also, rather than expressing 
full length Mcl-1, we expressed a 90 amino acid fragment 
(a.a. 157-246) encompassing the putative D-box. We 
reasoned that if this fragment could compete with the 
endogenous protein for APC/C-Cdc20 binding, this might 
delay degradation of endogenous Mcl-1 and thus delay 
DiM. By contrast, if the RALA mutant was deficient for 
APC/C-Cdc20 binding, then it should have no effect on 
DiM. Note that this approach is conceptually similar to 
the experiment that laid the foundation for the discovery 
of Securin whereby addition of a fragment of Cyclin B1 
containing the D-box to Xenopus egg extracts competed 
endogenous Cyclin and Securin away from APC/C-Cdc20, 
thereby inhibiting mitotic exit and anaphase onset [39]. 
To test this, RKO Cyclin B1 R42A cells were transiently 
transfected with constructs expressing mCherry-tagged 
Mcl-1 fragments, treated with taxol and cells entering 
mitosis were analyzed by time-lapse microscopy. Analysis 
of the cumulative death frequency in control cells or 
those transfected with mCherry alone showed that the 
time taken for 50% of the cells to undergo DiM (i.e. the 
T50) was 14.2 hours (Fig. 3C). Overexpressing the Mcl-1 
fragment extended the T50 to 19.3 hours. Strikingly, this 
was reversed by mutating the RXXL motif; analysis of 
the RALA fragment showed that the T50 was reduced 
to 11.5 hours. One explanation for these observations 
is that endogenous Mcl-1 interacts with APC/C-Cdc20 
and that overexpressing the D-box fragment, but not the 
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Figure 2: Analysis of E3 ligases implicated in mitotic degradation of Mcl-1. A. Cell fate profiles of RKO Cyclin B1 R42A cells 
treated with APC/C-Cdc20 inhibitors proTAME and/or Apcin for 72 hours using concentrations indicated. Zero hours represents mitotic 
entry. B. Cell fate profiles of RKO Cyclin B1 R42A cells co-treated with proTAME, Apcin and the Mps1 inhibitor AZ3146 for 72 hours. 
Zero hours represents mitotic entry. C. Cumulative death frequency of RKO Cyclin B1 R42A cells co-treated with taxol, tetracycline and 
proTAME/Apcin. Mann-Whitney U test, p > 0.05 D. Immunoblot of Mcl-1 levels in RKO Cyclin B1 R42A cells after 16 hours co-treatment 
with 0.1μM taxol, 1 μg/ml tetracycline and proTAME/Apcin at concentrations indicated. MG132 was added after 10 hours treatment. E. 
Cumulative death frequency graph of RKO Cyclin B1 R42A FBW7 RNAi cells exposed to proTAME/Apcin, 0.1μM taxol and 1 μg/ml 
tetracycline. Mann Whitney U test, ns p > 0.05. F. Immunoblot showing Mcl-1 and FBW7 levels in RKO Cyclin B1 R42A cells following 
transfection with FBW7 siRNA followed by exposure to proTAME/Apcin, 0.1μM taxol and 1 μg/ml tetracycline for 16 hours. Interphase 
sample was taken at zero hours.
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Mcl-1RALA fragment, acts as a competitor thus inhibiting 
Mcl-1 degradation and thereby extending time to death. 
Consistently, expression of the D-box fragment, but not 
the Mcl-1RALA fragment, stabilized endogenous Mcl-1 
during a taxol-mediated arrest (Fig. 3D).
Taken together, these observations suggest that 
while Mcl-1 may indeed engage with APC/C-Cdc20, the 
significance is unclear. In particular, while overexpressing 
the RXXL fragment supports an interaction between 
Mcl-1 and APC/C-Cdc20, the experiments analyzing full 
length Mcl-1 expressed at more physiological levels do 
not support the notion. Moreover, as described above, in 
our hands, inhibiting APC/C-Cdc20 had no obvious affect 
on Mcl-1 degradation or time to death.
Examination of a lysine-less Mcl1 mutant
In our hands, inhibiting three E3 ligases previously 
implicated in mitotic Mcl-1 degradation had no obvious 
effect on Mcl-1 levels or the time to DiM. If this was due 
to redundancy and/or the involvement of additional E3 
enzymes, we predicted that a lysine-less Mcl-1 should be 
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Figure 3: Analysis of Mcl-1’s putative D-box. A. Immunoblot of endogenous Mcl-1 (lower panel) and GFP-tagged Mcl1 (upper 
panel) following 24-hour 1 μg/ml tetracycline induction. B. Quantitation of time to mitotic death of RKO cells expressing Mcl-1WT and 
Mcl-1RALA following incubation with 0.1μM taxol and 1 μg/ml tetracycline. Zero hours represents mitotic entry. Mann Whitney U test, ns 
p > 0.05. C. Cumulative death frequency of RKO Cyclin B1 R42A cells transiently transfected with pLNCX2 plasmids expressing myc-
tagged mCherry fused to Mcl-1 competitor fragments (a.a. 157-246) with or without the RALA mutation. Transfected cells were identified 
by fluorescent microscopy and tracked by phase contrast microscopy. Mann Whitney U test between mCherry WT and mCherry RALA, 
**** p < 0.0001. D. Quantitation of two independent immunoblots showing relative Mcl-1 levels in RKO Cyclin B1 R42A cells transiently 
transfected with the mCherry-Mcl-1 WT and RALA fragments exposed to 0.1 μM taxol for the times indicated.
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non-degradable and therefore resist mitotic proteolysis 
and thus extend time to death in taxol-treated cultures. 
To test this, we generated stable tet-inducible RKO cell 
lines expressing either wild type Mcl-1 or a lysine-less 
mutant [40] whereby all 14 lysines are mutated to arginine 
(Mcl-1 ∆Lys, Fig. 4A). Significantly, while both wild type 
and the lysine-less mutant delayed the time to DiM, they 
did so to the same extent (Fig. 4B). This suggests that 
mitotic degradation of Mcl-1 during mitosis may not be 
mediated by the canonical ubiquitin-proteasome pathway. 
Note that previously, Stewart et al showed that the lysine-
less Mcl-1 is also degraded in interphase cells in a manner 
comparable to the wild type protein [40].
Mcl-1 levels influence slippage
Overexpressing the Mcl-1 fragment containing the 
putative D-box suggests that while Mcl-1 may not be a 
bona fide E3 ligase substrate, it can engage APC/C-Cdc20 
during a prolonged mitotic arrest. While the significance 
of this in the context of regulating DiM is unclear, we 
reasoned that if it was D-box-dependent it might influence 
the interaction between Cyclin B1 and APC/C-Cdc20, and 
thus influence slippage. To test this, we turned to DLD-1 
cells, another colon cancer cell line that tends to undergo 
slippage following a prolonged arrest [10]. Note that 
as in RKO cells, Mcl-1 protein levels decline in DLD-
1 cells arrested in mitosis (Fig. 5A). First, we inhibited 
Mcl-1 by RNAi (Fig. 5B) then added AZ138, an Eg5 
kinesin inhibitor. In the control population, 80% of cells 
underwent slippage (Fig. 5C). Of these, 10% then died in 
the following interphase. Upon RNAi-mediated inhibition 
of Mcl-1, a similar proportion (74%) underwent slippage, 
but of these 62% then died in interphase, demonstrating 
that Mcl-1 is an important post-mitotic survival factor, at 
least in this context. Strikingly, RNAi-mediated inhibition 
of Bcl-xL shifted the fate profile from slippage to DiM, 
indicating that Bcl-xL is an essential mitotic survival 
factor in DLD-1 cells. By contrast, note that in RKO cells, 
Mcl-1 compensates for Bcl-xL loss during a prolonged 
arrest (Fig. S1F and see also [32]). Interestingly, 
comparing RKO and DLD-1 with four additional cell 
lines showed a provocative correlation between relative 
Mcl-1 levels and slippage. Specifically, both DLD-1 and 
HCT116, which are slippage prone in the presence of taxol 
(Fig. S4A), have relatively low levels of Mcl-1 (Fig. S4B) 
and are resistant to Mcl-1 RNAi (Fig. S5). By contrast, 
RKO, HeLa, HT29 and H1703, which more are prone to 
death in mitosis (Fig. S4A), have relatively higher levels 
of Mcl-1 (Fig. S4B).
Because Mcl-1-deficient DLD-1 cells still 
underwent slippage, we measured the time from mitotic 
entry to exit to determine if slippage kinetics were 
affected. Analysis of the cumulative slippage frequency 
showed that the time taken for 50% of the control cells 
to slip (i.e. the T50) was 19.0 hours. Mcl-1 RNAi reduced 
the T50 to 14.7 hours (Fig. 5D). Thus, suppressing 
Mcl-1 levels accelerates slippage. We therefore asked 
whether artificially elevating Mcl-1 levels would have 
the opposite effect, i.e. delay slippage. To test this we 
generated tet-inducible DLD-1 lines expressing either 
wild type Mcl-1 or the Mcl-1RALA mutant (Fig 5E). 
Induction of the wild type protein delayed slippage by 
3.7 hours (Fig 5F). By contrast the Mcl-1RALA mutant 
had no impact on the T50 (Fig. 5G). Thus, artificially 
elevating Mcl-1 levels does indeed delay slippage 
and this effect appears to require the putative D-box. 
One possible explanation for these observations is that 
Mcl-1 competes with Cyclin B1 for APC/C-Cdc20 
binding in a D-box dependent manner such that when 
Mcl-1 levels are reduced, Cyclin B1 is degraded faster 
thereby accelerating slippage. Conversely when Mcl-1 
is overexpressed, Cyclin B1 degradation is inhibited, 
thereby delaying slippage.
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Suppressing Mcl-1 rescues delayed slippage 
induced by Bax/Bak depletion
The ability of Mcl-1 to influence slippage as 
shown above could help explain a recent and surprising 
observation, namely that that RNAi-mediated inhibition 
of Bax and Bak delayed slippage [41]. Because Mcl-
1 binds Bax and Bak (Fig. 6A and see also [42]), their 
removal by RNAi would be expected to liberate Mcl-1, 
thereby enabling it to engage with the APC/C-Cdc20 and/
or the proteasome and thus delay Cyclin B1 degradation. 
To test this we depleted Bax and Bak in DLD-1 cells 
and determined the cumulative slippage frequency (Fig. 
6B). Consistent with the recent report, Bax/Bak co-RNAi 
delayed the T50 for time to slippage from 18.3 hours to 21.1 
hours, indicating delayed slippage (Fig. 6C). Consistent 
with our data shown above, Mcl-1 RNAi reduced the T50 
to 14.7 hours, indicating accelerated slippage. Importantly, 
depleting Mcl-1 in Bax/Bak RNAi cells restored the 
time to slippage, with a T50 of 16.5 hours. Moreover, 
degradation of an mCherry D-box fusion [10] was 
accelerated following Mcl-1 RNAi, and this was partially 
rescued by co-depletion of Bax and Bak (Fig. S6). Thus, 
a simple explanation for the delayed slippage observed in 
Bax/Bak-deficient cells is the ability of liberated Mcl-1 
to compete with Cyclin B1 and thus slow degradation of 
the latter.
Elevating Mcl-1 levels delays both death in 
mitosis and slippage
We previously showed that there is extensive 
inter-line variation in terms of how different cancer 
cell lines respond to a protracted mitotic arrest [10]. 
By using RKO and DLD-1 cells for the experiments 
described above, we exploited this inter-line variation to 
focus on DiM and slippage respectively; whereas RKO 
typically undergo DiM, DLD-1 are slippage prone. Our 
observations show that overexpressing Mcl-1 can delay 
DiM in RKO and delay slippage in DLD-1. In principle 
therefore, overexpressing Mcl-1 should delay DiM as 
well as slippage in DLD-1 cells. To test this, we re-tuned 
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the DLD-1 experimental system to favor DiM instead of 
slippage. Rather than using an Eg5 inhibitor, we used a 
high dose of nocodazole; under these conditions, 64% of 
the DLD-1 cells underwent DiM, presumably due to super-
activation of the SAC and more penetrant APC/C-Cdc20 
inhibition (Fig. 7A). Tet-induction of wild type Mcl-1 had 
multiple effects. Firstly, of the cells that underwent DiM, 
time to death was delayed from 23.2 hours to 33.2 hours 
(Fig. 7B). Secondly, of the cells that underwent slippage, 
post-mitotic death was delayed from 10.3 hours to 27.1 
hours (Fig. 7C). Overexpressing the Mcl-1RALA mutant also 
delayed DiM from 27.5 hours to 35.4 hours (Fig. 7B).
The competing networks model predicts that 
delaying DiM provides more time for Cyclin B1 
degradation and should therefore shift the fate profile 
from DiM to slippage. Interestingly, overexpressing 
Mcl-1 only had a marginal effect on the proportion of 
cells undergoing slippage, from 36% in controls to 
44% (Fig. 7A). This modest effect could be because 
overexpressing Mcl-1 not only inhibits DiM but also 
slows Cyclin B1 degradation by engaging with the 
APC/C-Cdc20. Consistent with the Mcl-1RALA mutant not 
engaging APC/C-Cdc20, overexpression of Mcl-1RALA 
had a substantial effect on the number of cells undergoing 
slippage, increasing it from 48% in controls to 80% 
(Fig. 7A). Moreover, time to slippage was unaffected 
in DLD-1 cells expressing either wild type Mcl-1 or 
the RALA mutant (Fig. 7D). Thus, taken together, these 
results show that overexpressing Mcl-1 in DLD-1 cells 
delays both DiM and slippage, and that while the Mcl-
1RALA mutant is as effective at delaying DiM, it is less 
effective at delaying slippage. Although we have no 
direct evidence that wild type Mcl-1 binds Cdc20, these 
observations are consistent with the notion put forward 
by Harley et al, namely that Mcl-1 engages the APC/C-
Cdc20 in a D-box dependent manner [22].
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Delaying slippage enhances post-mitotic 
apoptosis
As noted above, overexpressing Mcl-1 in DLD-1 
cells delayed post-mitotic apoptosis (Fig 7A). Also, Mcl-
1 RNAi increased the proportion of cells undergoing 
post-mitotic apoptosis following slippage from 10% to 
62% (Fig. 5C). In addition, it was previously shown that 
inhibition of Mcl-1 suppresses cell cycle progression in 
interphase following nocodazole treatment [43]. This 
points at a post-mitotic survival role for Mcl-1. We 
therefore asked whether mitotic degradation of Mcl-1 
might also act as a post-mitotic death timer. If so, then the 
longer a cell spends arrested in mitosis, the more likely 
Mcl-1 levels are to fall such that even if it survives for 
long enough to undergo slippage, the more likely it is to 
die in interphase. If correct, one might expect there to be 
an inverse correlation between the time spent arrested in 
mitosis before slippage and the time from exit to death. 
Indeed, in some experimental conditions this does appear 
to be the case (Fig. S7). However, in other conditions 
there was no obvious correlation. We therefore set out to 
test more directly whether a longer mitotic arrest prior to 
slippage was more likely to induce post-mitotic death. 
To do this, we obtained a DLD-1 cell line constitutively 
expressing a myc-tagged OsTir transgene and generated 
derivatives expressing a tet-inducible stabilized Cyclin 
B1 R42A mutant fused to an AID tag so that it could be 
degraded at will by addition of IAA (Fig. S8A and see 
also [44, 45]). Quantitating GFP fluorescence indicated 
that 50% of the GFP-AID-Cyclin B1 R42A protein was 
degraded within 22 minutes following IAA treatment 
(Fig. S8B). When an uninduced population was exposed to 
the Eg5 inhibitor AZ138, 88% of cells arrested in mitosis 
and underwent slippage after an average of 14.8 hours 
(Fig. 8A). Upon tet-induction of GFP-AID-Cyclin B1 
R42A, 70% of the AZ138-treated cells underwent DiM 
with a mean arrest time of 29.6 hours. Addition of IAA at 
the same time as the tetracycline reverted this phenotype, 
consistent with IAA targeting the GFP-AID-Cyclin B1 
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R42A for SCF-Tir1-mediated degradation. Next, we tet-
induced GFP-AID-Cyclin B1 R42A, exposed the cells to 
AZ138 then added IAA either 20 or 30 hours later (Fig. 
8B). When the IAA was added after 20 hours, it took on 
average 6.9 hours for the cells to exit mitosis, presumably 
because despite degrading the AID-tagged exogenous 
Cyclin B1 R42A, there was sufficient endogenous Cyclin 
B1 to maintain the mitotic state for several hours. Indeed, 
when we added the IAA after 30 hours, it took only 2.4 
hours on average to trigger mitotic exit, consistent with 
further depletion of the endogenous protein; i.e. prior to 
addition of the IAA, the mitotic state was dependent on 
the exogenous GFP-AID-Cyclin B1 R42A. Moreover, 
prolonging the addition of IAA to 30 hours significantly 
extended the time to slippage (Fig. 8C). When the IAA 
was added after 20 hours, only 16% of the cells underwent 
post-mitotic death (Fig. 8B). By contrast, adding the IAA 
after 30 hours resulted in 42% of the cells undergoing 
post-mitotic death. Thus, adding IAA after 30 hours, 
allowed us to keep the cells in mitosis for long enough 
to deplete the endogenous Cyclin B1 but then drive them 
out before they underwent DiM. Under these conditions, 
cells were now much more likely to undergo post-
mitotic death. One explanation to account for this is that 
extending the mitotic arrest provided more time for Mcl-
1 degradation such that pro-survival function in the next 
interphase was compromised. However, it is also possible 
that extending the mitotic arrest provided more time for 
damage accumulation, regardless of Mcl-1 degradation 
[43, 46, 47]. Consistent with this latter notion, we noted 
that when the IAA was added after 20 hours, 60% of the 
cells entered a second mitosis. By contrast, adding the IAA 
after 30 hours resulted in only 7% of the cells entering a 
second mitosis. Nevertheless, these data strongly support 
the notion that the longer the duration of the mitotic arrest, 
the more likely it is that post-mitotic responses will be 
activated.
DISCUSSION
We set out to define Mcl-1’s role in mitotic cell fate 
determination. Initially, we focused on the role Mcl-1 
degradation plays in determining the onset of apoptosis 
during a prolonged mitotic arrest. Our observations 
confirm that Mcl-1 is an important mitotic survival factor: 
overexpressing Mcl-1 delays DiM and RNAi-mediated 
inhibition accelerates DiM. Our observations also confirm 
that Mcl-1 levels decline during a prolonged mitotic arrest. 
This decline is reduced when the proteasome is inhibited 
and accelerated when protein synthesis is suppressed. 
Importantly, when slippage is completely blocked, i.e. in 
taxol-treated cells expressing a stabilized form of Cyclin 
B1, inhibiting the proteasome has a strikingly penetrant 
effect, delaying DiM by many hours. Conversely, blocking 
protein synthesis accelerates DiM. Taken together, 
these observations indicate that Mcl-1 is continuously 
synthesized and degraded during a mitotic arrest, and 
that mitotic degradation of Mcl-1 could serve as the death 
timer evoked by the competing-networks model.
Canonical proteasome-mediated protein degradation 
depends on the ubiquitin system, and three E3 ubiquitin 
ligases have been implicated in targeting Mcl-1 for 
degradation during mitosis [22, 26, 29]. However, we 
have not been able to generate compelling evidence that 
APC/C-Cdc20, FBW7 or MULE are involved. Moreover, 
we have no compelling evidence that the activity of 
these ligases is required for DiM. This could reflect 
redundancy; however, simultaneously inhibiting all three 
E3 ligases had no obvious effect. Consistently, Shi et al 
reported only a mild effect upon co-inhibition of MULE 
and Cdc20 [29]. While we cannot rule out the possibility 
that the modalities employed here are simply not penetrant 
enough to block Mcl-1 ubiquitination, our observations 
raise the possibility that Mcl-1 is not a bona fide target of 
these E3 ligases during mitosis. Indeed, exogenous Mcl-1 
harboring a mutation in the putative D-box did not prolong 
survival over and above that of a wild type transgene. 
One possibility is that during mitosis, Mcl-1 is degraded 
in a proteasome-dependent manner that does not require 
ubiquitination. This notion is supported by an analysis 
of Mcl-1 in mouse embryo fibroblasts [40]. Stewart et 
al showed that Mcl-1 is degraded during interphase in a 
proteasome-dependent manner. However, an Mcl-1 mutant 
lacking all the lysine residues required for ubiquitination 
was degraded as efficiently as the wild type protein. 
Moreover, inhibiting the E1 ubiquitin-activating enzymes 
UAE and UBA6 had no effect on Mcl-1 degradation. And 
finally, an unmodified Mcl-1 substrate generated by in 
vitro transcription and translation was degraded by the 20S 
proteasome. Consistently, in our hands, the Mcl-1 mutant 
lacking lysine residues had no additional effect over and 
above the wild type control. Thus, although Mcl-1 may be 
ubiquitinated by multiple E3 ligases, it appears to be one 
of a growing list of proteins that can be degraded by the 
proteasome in an ubiquitin-independent manner [48]. This 
in turn provides a simple explanation for our observation 
showing that MG132 inhibits DiM in a Mcl-1-dependent 
manner but does not require APC/C-Cdc20, FBW7 or 
MULE.
The competing networks model, in its original 
formulation, proposed that the two networks responsible 
for mitotic cell fate are independent [10], a notion 
supported by predictive modeling [15]. However, a 
number of molecular interactions connect the mitotic 
and apoptotic pathways. For example, the master mitotic 
kinase Cdk-1 phosphorylates several apoptotic proteins 
including Caspase 9, Bcl-xL and Mcl-1 [21, 22, 49, 50]. In 
addition, Bim is targeted for degradation by APC/C-Cdc20 
[18]. These molecular interactions raise the possibility that 
there is crosstalk between the two networks. Indeed, it was 
recently shown that inhibiting the SAC silencer p31comet 
accelerated DiM, and that co-depletion of pro-apoptotic 
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Bax and Bak delayed slippage [41]. The possibility of 
crosstalk presents a technical challenge as experimental 
modulation of one network may influence the other, 
thereby complicating interpretations. Indeed, SAC 
genes frequently manifest in anti-mitotic siRNA survival 
screens [32, 41, 51, 52], not because they directly promote 
apoptosis but because they are required to prevent slippage 
[53], which in turn allows time for the accumulation of 
death signals [10].
To focus on the two networks separately, here we 
first focused on RKO cells which typically undergo DiM 
[10]. Importantly, expressing a non-degradable Cyclin B1 
in taxol-treated RKO cells completely blocked slippage, 
allowing us to use time-to-death to measure the integrity 
of the apoptotic network. Conversely, to focus on slippage 
we treated DLD-1 cells with an Eg5 inhibitor to create 
conditions which favor slippage [10]. These approaches 
demonstrate that experimentally altering Mcl-1 levels 
can influence both DiM and slippage, which on face 
value, appears to further support the notion of crosstalk. 
However, as discussed above, because degradation of 
Mcl1 in mitosis may be independent of an E3 ligase, it 
may not be a regulated phenomenon. Thus, the ability of 
Mcl-1 to influence slippage may be an epiphenomenon that 
arises during a prolonged mitotic arrest due to the presence 
of an RXXL motif that serves as a weak D-box allowing 
it to engage APC/C-Cdc20 in a non-regulated manner. If 
correct, the term crosstalk may be an over interpretation; 
we therefore suggest that in this case, network interference 
might be a more appropriate description.
The ability of Mcl-1 to be degraded by the 
proteasome independently of ubiquitination [40] may also 
provide alternative explanations for other observations that 
evoke crosstalk. For example, p31comet RNAi inhibits SAC 
silencing and super-inhibits APC/C-Cdc20 thus delaying 
slippage by further inhibiting proteasome-dependent 
degradation of Cyclin B1 [54, 55]. This may alleviate 
competition between Cyclin B1 and Mcl-1 for proteasome 
binding, thereby accelerating Mcl-1 degradation and 
advancing the onset of DiM. Conversely, by co-depleting 
Bax and Bak, the level of free Mcl-1 is expected to 
increase [56], which could then increase competition 
with Cyclin B1 thus slowing degradation of the latter 
and delaying slippage. Further evidence that there may 
not be genuine crosstalk comes from the recent discovery 
that the oncogenic transcription factor MYC is a major 
determinant of mitotic cell fate [32]. Specifically, MYC 
promotes the death-in-mitosis network by upregulating 
a cluster of redundant, pro-apoptotic BH3-only proteins, 
namely Bim, Bid and Noxa, and downregulating pro-
survival Bcl-xL. Importantly, while inhibiting MYC in 
RKO cells markedly delays DiM, it does not influence 
slippage [32]. Consequently, although inhibiting MYC 
promotes cell survival, the average amount of time spent 
arrested in mitosis increases from 17.1 to 21.3 hours. This 
supports the notion that the two networks responsible 
for mitotic cell fate are indeed independent. Moreover, 
by evoking the concept of network interference, our 
observations highlight the need for assays that can 
experimentally focus on DiM without interfering with 
slippage and vice versa.
EXPERIMENTAL PROCEDURES
Cell culture and drug treatments
Flp-In™ T-Rex™ DLD-1 and RKO cell lines were 
cultured as described [57]. HeLa, HCT116, HT-29 and 
H1703 were as described [10]. Flp-In™ T-Rex™ DLD-
1 cells expressing TIR1-9myc were kindly provided by 
Andrew Holland [44]. Tet-inducible isogenic stable 
lines were generated as described [58, 59]. In brief, 
pcDNA5/FRT/TO-based plasmids containing tagged 
human and mouse Mcl-1 and Cyclin B1 cDNAs were 
co-transfected with pOG44 into Flp-In™ T-Rex™ cell 
lines using Lipofectamine Plus™. Transfected cells 
were selected using 80 μg/ml hygromycin (Sigma) 
and 8 μg/ml blasticidin then colonies pooled. Small 
molecule inhibitors dissolved in DMSO were used at 
the following concentrations: taxol (0.1 μM; Sigma), 
AZ138 (1 μM; [10]), AZ127 (2 μM; Tocris), MG132 (20 
μM; Calbiochem), cycloheximide (30 μg/ml; Sigma), 
3-Indoleacetic acid (IAA, 500 μM; Sigma). Transgenes 
were induced with addition of 0.25-1 μg/ml tetracycline 
(Sigma). Cell synchronization in early S-phase was 
performed with 2 mM thymidine (Sigma).
Expression constructs
The human Mcl-1 open reading frame (ORF) was 
generated by RT-PCR using the Superscript® One-Step 
System (Life Technologies) with total RNA isolated 
from RKO cells and the following primers: Forward 
5’-ATGTTTGGCCTCAAAAGAAACGC-3’, reverse 
5’-GGTCTTATTAGATATGCC-3’. Site directed 
mutagenesis of the RXXL motif in Mcl-1 was performed 
using the Q5® Site-Directed mutagenesis kit following 
the manufacturers instructions with the following 
primers: 5’-TGGGGCCACCAGCGCGAAGGCGGCGG 
AGACCTTACGA-3’, 5’-TCGTAAGG TCTCCGCCGC 
CTTCGCGCTGGTGGCCCCA-3’. Standard molecular 
cloning techniques were used to insert the Mcl-1 ORF into 
pcDNA5/TO/GFP and pcDNA5/TO/GFP-AID vectors 
such that tags were fused to the C-terminus, placing 
the tagged ORFs downstream of a tet-regulatable CMV 
promoter. mCherry-Mcl-1 fragments encoding amino 
acids 157-246 were PCR amplified using the following 
primers: 5’-GACGGGTCACTACCCTCGACGCCG-3’, 
5’-CAACGATTTCACATCGTCTTCGTT-3’ and 
cloned into a pLNCX2-based vector containing 
an N-terminal myc-tag. Mouse Mcl-1 ORFs were 
PCR amplified using p3XFlag-CMV10-Flag vectors 
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(Addgene ID 32978 and 32979) and the following 
primers: 5’-TTTGGCCTGCGGAGAAACGCG-3’, 
5’-CTATCTTATTAGATATGCCAG-3’ and cloned into 
pcDNA5/FRT/TO.
RNAi and Transient transfections
For siRNA transfections, cells were seeded in a 
microclear 96 well plate (Greiner Bio-one) containing 
DharmaFECT 1 transfection reagent (Dharmacon), 
Opti-MEM (Life Technologies) and ON-TARGETplus 
SMARTpool siRNAs at a final concentration of 
66 nM (Dharmacon). Sequences of siRNAs were as 
follows: Mcl-1 (5’-CGAAGGAAGUAUCGAAUUU-3’, 
5’-GAUUAUCUCUCGGUACCUU-3’, 5’-GAAGGUGG 
CAUCAGGAAUG-3’, 5’-GGUUUGGCAUAUCUAAUA 
A-3’); Bcl-xL (5’-GGACAGCAUAUCAGAGCUU-3’, 
5’-GAAAUGACCAGACACUGAC-3’, 5’-CCUACAAG 
CUUUCCCAGAA-3’, 5’-UUAGUGAUGUGGAAGAG 
AA-3’); Bak (5’-CGACAUCAACCGACGCUAU-3’, 
5’-UAUGAGUACUUCACCAAGA-3’, 5’-GACGGCA 
GCUCGCCAUCAU-3’, 5’-AAUCAUGACUCCCAAGG 
GU-3’); Bax (5’-UGGGCUGGAUCCAAGACCA-3’, 
5’-CUGAGCAGAUCAUGAAGAC-3’, ACAUGUUU 
UCUGACGGCAA-3’, 5-GUGCCGGAACUGAUCAG 
AA-3’); FBW7 (5’-GGGCACCAGUCGUUAACAA-3’, 
5’-GUGAGUGGAUCUCUUGAUA-3’, 5’-GGAGUUG 
UGUGGCGGAUCA-3’, 5’-CAACAACGACGCCGAAU 
UA-3’); Non-targeting (5’-UGGUUUACAUGUCGA 
CUAA-3’, 5’-UGGUUUACAUGUUGUGUGA-3’, 5’-U 
GGUUUACAUGUUUUCUGA-3’, 5’-UGGUUUACAUG 
UUUUCCUA-3’). For transient transfections of plasmids, 
cells were plated 24 hours prior to transfection then 
transfections performed in antibiotic-free media with 
0.5 μg DNA and DharmaFECT reagent (Dharmacon). 
Following transfections, cells were incubated at 37°C 
for 24 hours before addition of anti-mitotic agents. For 
synchronization, thymidine was added to cells during the 
transfection procedure.
Immunoblotting
For immunoblotting, cells were seeded in 24 or 96 
well plates (Corning) then later harvested by trypsinisation, 
centrifuged, washed and lysed in SDS buffer (0.35 M 
Tris pH 6.8, 0.1 g/ml sodium dodecyl sulfate, 93 mg/ml 
dithiothreitol, 30% glycerol, 50 μg/ml bromophenol blue). 
Proteins were resolved by SDS-PAGE then electro-blotted 
onto Immobilion-P membranes (Millipore). Membranes 
were blocked in 5% dried milk in TBST (50 mM Tris, 
pH 7.6, 150 mM NaCl, 0.1% Tween-20) then incubated 
overnight at 4°C with the following primary antibodies 
diluted in milk: rabbit anti-Mcl-1 (Santa-Cruz), sheep 
anti-Tao1 [60], mouse anti-Cyclin B1 (Millipore), rabbit 
anti-Bcl-xL (Cell Signalling), sheep anti-Bub3 (Holland 
and Taylor, unpublished), rabbit anti-FBW7 (Bethyl), 
mouse anti-Bak (Calbiochem), rabbit anti-Bax (Santa-
Cruz), mouse anti-myc tag (4A6, Millipore), rabbit anti-
GFP (Cell Signalling). Following TBST washes, blots 
were incubated with appropriate horseradish-peroxidase-
conjugated secondary antibodies (Zymed). Bound 
secondaries were then detected by addition of EZ-ECL 
Chemiluminescence Reagent (Biological Industries) or 
Luminata™ Forte Western HRP Substrate (Millipore) and 
imaged using a Biospectrum 500 imaging system (UVP).
Immunoprecipitation
The ORF encoding a GFP-binder [61] was cloned 
into pGEX-4T3 then transformed into E.coli strain 
BL21. The GST-GFP-binder fusion protein was induced 
with IPTG, purified using Glutathione sepharose beads 
(Amintra), eluted using soluble glutathione then dialyzed. 
The purified GST-GFP-binder protein was then used to 
affinity purify GFP-tagged proteins using Glutathione 
sepharose beads. In brief, cells were plated into four 10 
cm dishes per condition, cultured for 24 hours followed 
by overnight induction of exogenous GFP-fused proteins 
using tetracycline. Cells were trypsinized, pooled and 
lysed in lysis buffer (0.1% Triton X-100, 100 mM NaCl, 
10 mM Tris pH7.4, 1 mM EDTA, 1mM EGTA, 20 mM 
β-Glycerol, 10 mM NaF) then insoluble proteins removed 
by centrifugation. To purify GFP-tagged proteins, a 50% 
Glutathione magnetic bead slurry was washed in protein 
lysis buffer, added to the lysate along with 30 μg of GST-
GFP-binder protein then incubated under rotation for 
three hours at 4°C. Beads were washed five times with 
lysis buffer then bound proteins eluted by boiling in SDS 
sample buffer. For input samples, 5% of the original 
supernatant was removed.
Time-lapse imaging
For cell fate profiling, cells were seeded onto 
microclear 96 well plates (Greiner) then analyzed using an 
IncuCyte ZOOM (Essen BioSciences) equipped with a 20x 
objective, acquiring images every 10 minutes. Confluency 
measurements were performed using the IncuCyte ZOOM 
software. Real time quantitation of apoptosis was also 
performed on an IncuCyte ZOOM in conjunction with 
CellPlayer Kinetic Caspase-3/7 Apoptosis Assay Kit 
(EssenBioSciences) [32]. To determine mitotic timing 
and cell fate, MPEG-4 image sequences were analyzed 
manually, scoring 50 cells per condition from duplicate 
wells. Zero hours represents when imaging started unless 
indicated otherwise. Cell fate profiles were generated 
using Graphpad Prism 6 [10]. For fluorescent analysis 
of DLD-1 cells expressing the mCherry D-box fusion 
[10], cells were seeded in a microclear 96 well plate 
(Greiner) prior to RNAi transfections. For transient 
transfections of mCherry-Mcl-1 fragments and fluorescent 
tracking of AID-tagged proteins, cells were seeded into a 
Oncotarget15www.impactjournals.com/oncotarget
24 well microclear plate (Ibidi) then live cell imaging of 
fluorescent cells performed on an Axiovert 200 microscope 
with a 32x objective (Zeiss) enclosed in an environmental 
control chamber (Solent) with cells maintained at 37°C in 
a continuous flow of humidified CO
2
 [62]. Images were 
taken using a CoolSNAP HQ camera (Photometrics) and 
analyzed using Metamorph software (Molecular Devices).
Quantitative polymerase chain reaction (qPCR)
RNA was extracted from cells using TRIzol-
chloroform (Invitrogen) according to the manufacturers 
instructions, precipitated using 100% isopropanol then 
re-suspended in RNase-free water. Samples were DNase-
treated and reverse transcribed using random hexamers, 
Reverse Transcriptase and RNase inhibitor (all Qiagen). 
Amplification of specific cDNAs was performed on 
an Mx3000P qPCR system (Agilent Technologies) 
using SYBR green (Qiagen) and the following primers: 
MULE (5’-GGGGTTATGACCCAAGAGGT-3’, 
5’-CCCATCTCGAGACTCCTCTG-3’); GAPDH 
(5’-CCACCCATGGCAAATTCCATGGCA-3’, 
5’-TCTAGACGGCAGGTCAGGTCCACC-3’). Analysis 
was performed using the delta CT method.
Statistical tests
Cumulative frequency plots and statistical analyses 
(non-parametric Mann-Whitney U tests) were performed 
on Graphpad Prism 6. Box-and-whisker plots show the 
mean and the interquartile ranges.
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